Aggressive serrated BRAF-mutated/CIMP-positive/MSS tumors will probably necessitate more aggressive treatment and, potentially, different treatment agents than CRC exhibiting high levels of MSI or CRC resulting from the traditional adenoma–carcinoma sequence. The gene discussed is BRAF; the disease is colorectal carcinoma.